A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Daily CF101 Administered Orally for 12 Weeks to Patients With Osteoarthritis of the Knee

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Daily CF101 Administered Orally for 12 Weeks to Patients With Osteoarthritis of the Knee

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2015 Last checked against ClinicalTrials.gov record.
    • 16 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019 as reported by ClinicalTrials.gov.
    • 16 Dec 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top